Test Identifies Patients With Melanoma Tumors

October 2011
Worldwide Biotech;Oct2011, Vol. 23 Issue 10, p2
Trade Publication
The article offers information on the cobas BRAF Mutation Test, a companion diagnostic developed by Roche that detect melanoma tumors that contain a mutated form of the BRAF gene.


Related Articles

  • Roche selects Quidel flu test for FluSTAR.  // Medical Device Daily;10/3/2008, Vol. 12 Issue 211, p6 

    The article reports on decision of Roche to select the QuickVue brand Influenza A+B test of Quidel for the FluSTAR surveillance program during the 2008-2009 flu season. Sponsored by Roche since 1999, FluSTAR is a comprehensive influenza surveillance network program which was developed by SDI to...

  • Cardiac Markers.  // Clinical Lab Products;Feb2008, Vol. 38 Issue 2, p40 

    The article features several cardiac monitoring technologies, including the Rapid Analyte Measurement Platform (RAMP) system from Response Biomedical Corp., Cardiasure cardiac markers controls from Quantimetrix Corp., and NT-proBNP from Roche.

  • Roche LightCycler test for MRSA garners CE mark.  // Medical Device Daily;4/3/2009, Vol. 13 Issue 63, p9 

    The article report on the CE mark received by Roche for its new LightCycler test for the detection of methicillin-resistant Staphylococcus aureus. The said test is characterized as an in vitro diagnostic test designed to detect nasal colonization with MRSA. The test can be performed on Roche's...

  • SNDA FILED FOR XENICAL AS TYPE 2 DIABETES TREATMENT OPTION.  // Worldwide Biotech;May2001, Vol. 13 Issue 5, p3 

    Reports that Roche has announced that a supplemental New Drug Application has been submitted to the United States Food and Drug Administration for Xenical.

  • Roche moves OTC work in central Europe to Saatchi.  // Advertising Age's Euromarketing;8/6/96, Vol. 9 Issue 47, p1 

    Reports that Roche Consumer Health of eastern Europe has awarded Saatchi & Saatchi the advertising accounts for its Supradyn, Rennie, Aspro and Bepanthene brands. Value of the account.

  • Roche invests in proteomics programme.  // Life Science Today;Dec2000, Vol. 1 Issue 6, p7 

    Focuses on the total amount of money allotted by Roche to link proteomics research in the pharmaceuticals and diagnostics division of the company in Switzerland. Description of proteomics; Accounts on the gene function in the post-genomic era; Identification of the protein used as potential...

  • Roche. Valdmanis, Thor // Financial World;5/20/96, Vol. 165 Issue 8, p24 

    Features Swiss drugmaker Roche. Merger of Roche's rivals Sandoz and Ciba-Geigy; Displacement of Roche as a Switzerland's top pharmaceutical concern; Growing trend towards large pharmaceutical companies worldwide.

  • No sale.  // WWD: Women's Wear Daily;2/7/1997, Vol. 173 Issue 26, p10 

    Reports on the impact of Roche Holdings Ltd.'s announcement to acquire a United States-based flavors business on speculations about the sale of Givaudan-Roure, its fragrance flavors division.

  • Roche rush.  // njbiz;7/2/2012, Vol. 25 Issue 27, p11 

    The article contends that to say that the decision of pharmaceutical company Roche to close its Nutley, New Jersey, operation came as a shock would be an understatement.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics